Complications of HIV infection in an ageing population: Challenges in managing older patients on long-term combination antiretroviral therapy

Journal of Antimicrobial Chemotherapy

Volumn 66, Issue 6, 2011, Pages 1210-1214

  Zhao, Hui ^a,b   Goetz, Matthew Bidwell ^b,c  

^a CEDARS SINAI MEDICAL CENTER   (United States)

^b VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Age; Epidemiology; Immunocompromised host

Indexed keywords

ABACAVIR; ATAZANAVIR; CHOLESTEROL; DIDANOSINE; EFAVIRENZ; FOSAMPRENAVIR; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INDINAVIR; LOPINAVIR PLUS RITONAVIR; NEVIRAPINE; RITONAVIR; STAVUDINE; TENOFOVIR; TESTOSTERONE; TRIACYLGLYCEROL; VIRUS RNA; ZALCITABINE; ZIDOVUDINE;

ABDOMINAL OBESITY; ACQUIRED IMMUNE DEFICIENCY SYNDROME; AGE; AGED; ANEMIA; ANUS CANCER; BLOOD PRESSURE; BONE DENSITY; CD4 LYMPHOCYTE COUNT; CHOLESTEROL BLOOD LEVEL; CHRONIC KIDNEY DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CIGARETTE SMOKING; COMORBIDITY; DEMENTIA; DIABETES MELLITUS; DISEASE COURSE; DISEASE EXACERBATION; DRUG HYPERSENSITIVITY; DYSLIPIDEMIA; FRACTURE; GERIATRIC PATIENT; GLOMERULUS FILTRATION RATE; GROUPS BY AGE; HEART INFARCTION; HEPATITIS B; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HODGKIN DISEASE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPOGONADISM; IMMUNE DEFICIENCY; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; INSULIN RESISTANCE; KIDNEY DISEASE; KIDNEY FAILURE; LIPODYSTROPHY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER TOXICITY; LUNG CANCER; MEDICAL HISTORY; METABOLIC SYNDROME X; MIXED INFECTION; MORTALITY; MOUTH CANCER; NEPHROTOXICITY; OSTEOPENIA; OSTEOPOROSIS; PATIENT CARE; PRACTICE GUIDELINE; PULMONARY HYPERTENSION; REVIEW; SIDE EFFECT; TESTOSTERONE BLOOD LEVEL; TREATMENT DURATION; TREATMENT RESPONSE; TRIACYLGLYCEROL BLOOD LEVEL; VIRUS REPLICATION; VITAMIN D DEFICIENCY;

AGED; AGED, 80 AND OVER; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CARDIOVASCULAR DISEASES; CD4 LYMPHOCYTE COUNT; DISEASE PROGRESSION; HIV INFECTIONS; HUMANS; LIVER DISEASES; MIDDLE AGED;

EID: 79956024567     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkr058     Document Type: Review

References (68)

1. CDC. HIV/AIDS Surveillance Report, 2008. http://www.cdc.gov/hiv/surveillance/resources/reports/2008report/pdf/2008SurveillanceReport.pdf (16 June 2010, date last accessed).
2. Smith RD, Delpech VC, Brown AE et al. IV transmission and high rates of late diagnoses among adults aged 50 years and over. AIDS 2010; 24: 2109-15.
3. Kirk JB, Goetz MB. Human immunodeficiency virus in an aging population, a complication of success. J Am Geriatr Soc 2009; 57: 2129-38.
4. Aberg JA. Cardiovascular complications in HIV management: past, present, and future. J Acquir Immune Defic Syndr 2009; 50: 54-64.
5. Touloumi G, Pantazis N, Babiker AG et al. Differences in HIV RNA levels before the initiation of antiretroviral therapy among 1864 individuals with known HIV-1 seroconversion dates. AIDS 2004; 18: 1697-705.
6. CASCADE Collaboration. Differences in CD4 cell counts at seroconversion and decline among 5739 HIV-1-infected individuals with well-estimated dates of seroconversion. J Acquir Immune Defic Syndr 2003; 34: 76-83.
7. Phillips A. Short-term risk of AIDS according to current CD4 cell count and viral load in antiretroviral drug-naive individuals and those treated in the monotherapy era. AIDS 2004; 18: 51-8.
8. Collaboration of Observational HIV Epidemiological Research Europe (COHERE) Study Group. Response to combination antiretroviral therapy: variation by age. AIDS 2008; 22: 1463-73.
9. Silverberg MJ, Leyden W, Horberg MA et al. Older age and the response to and tolerability of antiretroviral therapy. Arch Intern Med 2007; 167: 684-91.
10. Phillips AN, Neaton J, Lundgren JD. The role of HIV in serious diseases other than AIDS. AIDS 2008; 22: 2409-18.
11. Goulet JL, Fultz SL, Rimland D et al. Aging and infectious diseases: do patterns of comorbidity vary by HIV status, age, and HIV severity? Clin Infect Dis 2007; 45: 1593-601.
12. Neuhaus J, Angus B, Kowalska JD et al. Risk of all-cause mortality associated with nonfatal AIDS and serious non-AIDS events among adults infected with HIV. AIDS 2010; 24: 697-706.
13. Sabin CA, Smith CJ, Delpech V et al. The associations between age and the development of laboratory abnormalities and treatment discontinuation for reasons other than virological failure in the first year of highly active antiretroviral therapy. HIV Med 2009; 10: 35-43.
14. Lodwick RK, Smith CJ, Youle M et al. Stability of antiretroviral regimens in patients with viral suppression. AIDS 2008; 22: 1039-46.
15. Kuller LH, Tracy R, Belloso W et al. Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med 2008; 5: e203.
16. Lodwick RK, Sabin CA, Porter K et al. Death rates in HIV-positive antiretroviral-naive patients with CD4 count greater than 350 cells per microL in Europe and North America: a pooled cohort observational study. Lancet 2010; 376: 340-5.
17. Weber R, Sabin CA, Friis-Moller N et al. Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. Arch Intern Med 2006; 166: 1632-41.
18. Reekie J, Kosa C, Engsig F et al. Relationship between current level of immunodeficiency and non-acquired immunodeficiency syndromedefining malignancies. Cancer 2010; 116: 5306-15.
19. Triant VA, Regan S, Lee H et al. Association of immunologic and virologic factors with myocardial infarction rates in a US healthcare system. J Acquir Immune Defic Syndr 2010; 55: 615-9.
20. Lichtenstein KA, Armon C, Buchacz K et al. Low CD4+ T cell count is a risk factor for cardiovascular disease events in the HIV outpatient study. Clin Infect Dis 2010; 51: 435-47.
21. Lundgren JD, Babiker A, el-Sadr W et al. Inferior clinical outcome of the CD4+ cell count-guided antiretroviral treatment interruption strategy in the SMART study: role of CD4+ Cell counts and HIV RNA levels during follow-up. J Infect Dis 2008; 197: 1145-55.
22. Smith C. Factors associated with specific causes of death amongst HIV-positive individuals in the D:A:D Study. AIDS 2010; 24: 1537-48.
23. Triant VA, Lee H, Hadigan C et al. Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease. J Clin Endocrinol Metab 2007; 92: 2506-12.
24. Calza L, Manfredi R, Verucchi G. Myocardial infarction risk in HIV-infected patients: epidemiology, pathogenesis, and clinical management. AIDS 2010; 24: 789-802.
25. Worm SW, Sabin C, Weber R et al. Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study. J Infect Dis 2010; 201: 318-30.
26. Lang S, Mary-Krause M, Cotte L et al. Impact of individual antiretroviral drugs on the risk of myocardial infarction in human immunodeficiency virus-infected patients: a case-control study nested within the French Hospital Database on HIV ANRS cohort CO4. Arch Intern Med 2010; 170: 1228-38.
27. Friis-Moller N, Reiss P, Sabin CA et al. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med 2007; 356: 1723-35.
28. Bedimo R, Westfall A, Drechsler H et al. Abacavir use and risk of acute myocardial infarction and cerebrovascular disease in the HAARTera. http://www.aegis.com/conferences/iashivpt/2009/MOAB202.pdf (18 January 2011, date last accessed).
29. Brothers CH, Hernandez JE, Cutrell AG et al. Risk of myocardial infarction and abacavir therapy: no increased risk across 52 GlaxoSmithKline-sponsored clinical trials in adult subjects. J Acquir Immune Defic Syndr 2009; 51: 20-8.
30. Martin A, Bloch M, Amin J et al. Simplification of antiretroviral therapy with tenofovir-emtricitabine or abacavir-lamivudine: a randomized, 96-week trial. Clin Infect Dis 2009; 49: 1591-601.
31. De Wit S, Sabin CA, Weber R et al. Incidence and risk factors for new onset diabetes mellitus in HIV infected patients: the D:A:D study. Diabetes Care 2008; 31: 1224-9.
32. Brown TT, Cole SR, Li X et al. Antiretroviral therapy and the prevalence and incidence of diabetes mellitus in the multicenter AIDS cohort study. Arch Intern Med 2005; 165: 1179-84.
33. Tien PC, Schneider MF, Cole SR et al. Antiretroviral therapy exposure and incidence of diabetes mellitus in the Women's Interagency HIV Study. AIDS 2007; 21: 1739-45.
34. Samaras K. Prevalence and pathogenesis of diabetes mellitus in HIV-1 infection treated with combined antiretroviral therapy. J Acquir Immune Defic Syndr 2009; 50: 499-505.
35. Brar I, Shuter J, Thomas A et al. A comparison of factors associated with prevalent diabetes mellitus among HIV-infected antiretroviralnaive individuals versus individuals in the National Health and Nutritional Examination Survey cohort. J Acquir Immune Defic Syndr 2007; 45: 66-71.
36. Hammond E, McKinnon E, Nolan D. Human immunodeficiency virus treatment-induced adipose tissue pathology and lipoatrophy: prevalence and metabolic consequences. Clin Infect Dis 2010; 51: 591-9.
37. Crane HM, Grunfeld C, Harrington RD et al. Lipoatrophy and lipohypertrophy are independently associated with hypertension. HIV Med 2009; 10: 496-503.
38. Simard EP, Pfeiffer RM, Engels EA. Spectrum of cancer risk late after AIDS onset in the United States. Arch Intern Med 2010; 170: 1337-45.
39. Silverberg M, Xu L, Chao C et al. Immunodeficiency, HIV RNA levels, and risk of non-AIDS-defining cancers. http://www.retroconference.org/2010/Abstracts/38117.htm (17 February 2010, date last accessed).
40. Sulkowski MS. Management of hepatic complications in HIV-infected persons. J Infect Dis 2008; 197 Suppl 3: S279-93.
41. Longenecker CT, Scherzer R, Bacchetti P et al. HIV viremia and changes in kidney function. AIDS 2009; 23: 1089-96.
42. Mocroft A, Kirk O, Reiss P et al. Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients. AIDS 2010; 24: 1667-78.
43. Goicoechea M, Zheng Y, Hughes M et al. Antiretroviral regimen and pharmacogenetic determinants of tenofovir-associated change in creatinine clearance in ACTG protocol A5142. http://pag.aids2010.org/Abstracts.aspx?SID=202&AID=6093 (18 January 2011, date last accessed).
44. Brown TT, Qaqish RB. Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review. AIDS 2006; 20: 2165-74.
45. Brown TT, McComsey GA, King MS et al. Loss of bone mineral density after antiretroviral therapy initiation, independent of antiretroviral regimen. J Acquir Immune Defic Syndr 2009; 51: 554-61.
46. Duvivier C, Kolta S, Assoumou L et al. Greater decrease in bone mineral density with protease inhibitor regimens compared with nonnucleoside reverse transcriptase inhibitor regimens in HIV-1 infected naive patients. AIDS 2009; 23: 817-24.
47. Borderi M, Gibellini D, Vescini F et al. Metabolic bone disease in HIV infection. AIDS 2009; 23: 1297-310.
48. Mueller NJ, Fux CA, Ledergerber B et al. High prevalence of severe vitamin D deficiency in combined antiretroviral therapy-naive and successfully treated Swiss HIV patients. AIDS 2010; 24: 1127-34.
49. Dao CN, Patel P, Overton ET et al. Low vitamin D among HIV-infected adults: prevalence of and risk factors for low vitamin D levels in a cohort of HIV-infected adults and comparison to prevalence among adults in the US general population. Clin Infect Dis 2011; 52: 396-405.
50. Borderi M, Vescini F, Cozzi-Lepri A et al. Prevalence of hypovitaminosis D among HIV+ patients enrolled in a large Italian cohort. http://www.retroconference.org/2010/PDFs/751.pdf (18 January 2011, date last accessed).
51. Gallant JE, Staszewski S, Pozniak AL et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA 2004; 292: 191-201.
52. McComsey G, Kitch D, Daar E et al. Bone and limb fat outcomes of ACTG A5224s, a substudy of ACTG A5202: a prospective, randomized, partially blinded phase III trial of ABC/3TC or TDF/FTC with EFV or ATV/r for initial treatment of HIV-1 infection. http://www.retroconference.org/2010/Abstracts/39788.htm (18 January 2011, date last accessed).
53. Huang J, Hughes M, Riddler S et al. Effects of randomized regimen and nucleoside reverse transcriptase inhibitor (NRTI) selection on 96 week bone mineral density (BMD): results from ACTG 5142. http://www.iasociety.org/Default.aspx?pageId=11&abstractId=200738549 (18 January 2011, date last accessed).
54. Martin A, Smith DE, Carr A et al. Reversibility of lipoatrophy in HIV-infected patients 2 years after switching from a thymidine analogue to abacavir: the MITOX Extension Study. AIDS 2004; 18: 1029-36.
55. Womack J, Goulet J, Gibert C et al. HIV-infection and fragility fracture risk among male veterans. http://www.retroconference.org/2010/Abstracts/39138.htm (18 January 2011, date last accessed).
56. Triant VA, Brown TT, Lee H et al. Fracture prevalence among human immunodeficiency virus (HIV)-infected versus non-HIV-infected patients in a large U.S. healthcare system. J Clin Endocrinol Metab 2008; 93: 3499-504.
57. Valcour V, Shikuma C, Shiramizu B et al. Higher frequency of dementia in older HIV-1 individuals: the Hawaii Aging with HIV-1 Cohort. Neurology 2004; 63: 822-7.
58. Ellis R, Badiee J, Letendre S et al. Nadir CD4 is a predictor of HIV neurocognitive impairment (NCI) in the era of combination antiretroviral therapy (cART): results from the CHARTER study. http://www.iasociety.org/default.aspx?pageId=11&abstractId=200741325 (18 January 2011, date last accessed).
59. Crothers K, Butt AA, Gibert CL et al. Increased COPD among HIV-positive compared to HIV-negative veterans. Chest 2006; 130: 1326-33.
60. Dube MP, Parker RA, Mulligan K et al. Effects of potent antiretroviral therapy on free testosterone levels and fat-free mass in men in a prospective, randomized trial: A5005s, a substudy of AIDS Clinical Trials Group Study 384. Clin Infect Dis 2007; 45: 120-6.
61. Desquilbet L, Jacobson LP, Fried LP et al. HIV-1 infection is associated with an earlier occurrence of a phenotype related to frailty. J Gerontol A Biol Sci Med Sci 2007; 62: 1279-86.
62. Fried LP, Tangen CM, Walston J et al. Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci 2001; 56: M146-56.
63. Hoang T, Goetz MB, Yano EM et al. The impact of integrated HIV care on patient health outcomes. Med Care 2009; 47: 560-7.
64. Fultz SL, Goulet JL, Weissman S et al. Differences between infectious diseases-certified physicians and general medicine-certified physicians in the level of comfort with providing primary care to patients. Clin Infect Dis 2005; 41: 738-43.
65. Justice AC. HIV and aging: time for a new paradigm. Curr HIV/AIDS Rep 2010; 7: 69-76.
66. European AIDS Clinical Society (EACS). Guidelines for the Clinical Management and Treatment of HIV Infected Adults in Europe. http://www.europeanaidsclinicalsociety.org/guidelinespdf/EACS-EuroGuidelines_ FullVersion.pdf (28 January 2011, date last accessed).
67. Thompson MA, Aberg JA, Cahn P et al. Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. JAMA 2010; 304: 321-33.
68. DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in HIV-infected Adults and Adolescents. http://aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf (10 January 2011, date last accessed).